Intervention

Zoledronate

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting0

Common conditions10

Lead sponsors shown5

Clinical trials

7 shown

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)NCT03664687 · 2018-10-31

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast CancerNCT03358017 · 2018-03-05

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone MetastasesNCT02721433 · 2016-08-01

Pre-operative Zoledronate in Triple Negative Breast CancerNCT02347163 · 2015-02-03

Bone Loss Treatment From Adjuvant Zoledronate EfficacyNCT01623908 · 2011-07-01

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral DensityNCT00102908 · 2005-05-01

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast CancerNCT00213980 · 2000-01-01

Common conditions

Breast Cancer3 Bone Loss1 Breast Neoplasms1 Early-stage Breast Cancer1 HIV Infections1 Metastasis1 Osteopenia1 Osteoporosis1 Prostate Cancer1 Triple Negative Breast Cancer1

Leading sponsors

Mario Negri Institute for Pharmacological Research2 Ottawa Hospital Research Institute2 First Affiliated Hospital, Sun Yat-Sen University1 National Institute of Allergy and Infectious Diseases (NIAID)1 University of Wisconsin, Madison1

Trial status mix

COMPLETED4

TERMINATED2

UNKNOWN1

Phase mix

PHASE24

PHASE42

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.